Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or Alendronate

CONTEXT: In postmenopausal osteoporotic women, denosumab fully inhibits teriparatide-induced bone resorption at approved doses. This property of denosumab is distinct from that of alendronate and likely contributes to the efficacy of combination denosumab and teriparatide therapy. Whether denosumab...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Endocrinol Metab
Autors principals: Tsai, Joy N., Zhu, Yuli, Foley, Katelyn, Lee, Hang, Burnett-Bowie, Sherri-Ann, Neer, Robert M., Leder, Benjamin Z.
Format: Artigo
Idioma:Inglês
Publicat: Endocrine Society 2015
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5393530/
https://ncbi.nlm.nih.gov/pubmed/25933031
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2015-1541
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars